Source comparison
Ipamorelin Versus MK-677: Peptide Pulse Versus Oral Saturation
The most instructive within-class comparison is between Ipamorelin and MK-677 (ibutamoren), because MK-677 is the one member of the ghrelin-mimetic family that has been through a rigorous, long-duration, controlled human trial — and its results are a sobering
This comparison does not assign a generated winner or score.
- The most instructive within-class comparison is between Ipamorelin and MK-677 (ibutamoren), because MK-677 is the one member of the ghrelin-mimetic family that has been through a rigorous, long-duration, controlled human trial — and its results are a sobering lesson in how a clean GH-raising mechanism behaves when finally tested against real clinical endpoints.
- MK-677 is an orally active, non-peptide ghrelin-receptor agonist. Because it is small and orally bioavailable, it can be taken as a daily tablet and produces a sustained elevation of GH and IGF-1, in contrast to Ipamorelin’s injected, pulse-like action. The pivotal study was Nass and colleagues’ two-year, double-blind, randomized, placebo-controlled trial in 65 healthy older adults, published in Annals of Internal Medicine in 2008.5 Over twelve months, MK-677 enhanced pulsatile GH secretion, restored IGF-1 toward young-adult levels, and significantly increased fat-free mass by roughly 1.6 kg — a genuine, statistically real change in body composition. That is arguably the strongest single piece of human evidence that any ghrelin-mimetic can move a body-composition endpoint.
- And yet the trial is also a cautionary tale, which is exactly why it matters for evaluating Ipamorelin. The increase in fat-free mass did not translate into improved muscle strength or better functional outcomes, and the compound worsened insulin sensitivity and raised fasting glucose in some participants.5 In other words, the best-studied member of Ipamorelin’s own receptor class raised the right hormones and even changed the scale reading for lean mass, but failed to produce the functional benefit that would justify calling it a therapy, and introduced a metabolic downside. The lesson generalizes: raising GH and IGF-1, even successfully and durably, is not automatically the same as producing a clinically meaningful outcome.
- Class
- Selective peptide ghrelin-receptor agonist
- Peptide ghrelin-receptor agonists
- Oral non-peptide ghrelin mimetic
- GH-releasing potency
- Comparable to GHRP-61
- High; GHRP-2/hexarelin exceed max GHRH10
- Sustained GH/IGF-1 elevation5
- Cortisol / ACTH / prolactin
- No significant rise1
- Reproducible mild increases10
- Relatively GH-focused; metabolic effects noted5
- Route
- Subcutaneous (research)
- Subcutaneous / nasal (research)
- Oral5
- Best human evidence
- Phase 2 postoperative-ileus trial (failed primary endpoint)6
- Human pharmacology, no approved indication
- 2-year RCT: +lean mass, no strength gain, worse insulin sensitivity5
- Regulatory status
- Not FDA/EMA approved
- Not approved; WADA-prohibited class
- Not FDA approved
- The table makes the central point visible. Ipamorelin’s advantage over its peptide cousins is selectivity; its disadvantage relative to MK-677 is that it has never been tested in anything approaching a two-year clinical trial. On the question the title poses — what makes Ipamorelin precise — the answer is clear and well-evidenced. On the unspoken follow-up — whether that precision produces benefit — the honest answer is that the best evidence in the whole class (MK-677’s) shows how easily GH elevation fails to become clinical value.